KR20150027752A - 인간화된 il-7 설치류 - Google Patents
인간화된 il-7 설치류 Download PDFInfo
- Publication number
- KR20150027752A KR20150027752A KR1020147035047A KR20147035047A KR20150027752A KR 20150027752 A KR20150027752 A KR 20150027752A KR 1020147035047 A KR1020147035047 A KR 1020147035047A KR 20147035047 A KR20147035047 A KR 20147035047A KR 20150027752 A KR20150027752 A KR 20150027752A
- Authority
- KR
- South Korea
- Prior art keywords
- human
- humanized
- exon
- rodent
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 241000283984 Rodentia Species 0.000 title claims abstract description 141
- 241000282414 Homo sapiens Species 0.000 claims abstract description 244
- 108010002586 Interleukin-7 Proteins 0.000 claims abstract description 218
- 102000000704 Interleukin-7 Human genes 0.000 claims abstract description 181
- 210000004027 cell Anatomy 0.000 claims abstract description 55
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 32
- 230000001105 regulatory effect Effects 0.000 claims abstract description 23
- 210000004602 germ cell Anatomy 0.000 claims abstract description 11
- 101001043807 Homo sapiens Interleukin-7 Proteins 0.000 claims description 121
- 102000052622 human IL7 Human genes 0.000 claims description 121
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 95
- 241000699670 Mus sp. Species 0.000 claims description 73
- 241000700159 Rattus Species 0.000 claims description 33
- 108700024394 Exon Proteins 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 24
- 230000014509 gene expression Effects 0.000 claims description 21
- 238000011144 upstream manufacturing Methods 0.000 claims description 16
- 150000007523 nucleic acids Chemical group 0.000 claims description 15
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 14
- 238000006467 substitution reaction Methods 0.000 claims description 13
- 241000699800 Cricetinae Species 0.000 claims description 12
- 210000001519 tissue Anatomy 0.000 claims description 9
- 239000002299 complementary DNA Substances 0.000 claims description 7
- 210000001541 thymus gland Anatomy 0.000 claims description 6
- 108700019146 Transgenes Proteins 0.000 claims description 5
- 210000002980 germ line cell Anatomy 0.000 claims description 5
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 3
- 210000000936 intestine Anatomy 0.000 claims description 3
- 230000004048 modification Effects 0.000 claims description 3
- 238000012986 modification Methods 0.000 claims description 3
- 210000000981 epithelium Anatomy 0.000 claims description 2
- 241000894007 species Species 0.000 claims description 2
- 210000000952 spleen Anatomy 0.000 claims description 2
- 108091023045 Untranslated Region Proteins 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 101001043808 Mus musculus Interleukin-7 Proteins 0.000 abstract description 26
- 229940100994 interleukin-7 Drugs 0.000 abstract description 9
- 210000002257 embryonic structure Anatomy 0.000 abstract description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 73
- 108020004414 DNA Proteins 0.000 description 24
- 238000011830 transgenic mouse model Methods 0.000 description 23
- 101100508566 Homo sapiens IL7 gene Proteins 0.000 description 22
- 241000699660 Mus musculus Species 0.000 description 22
- 239000012634 fragment Substances 0.000 description 17
- 230000002093 peripheral effect Effects 0.000 description 15
- 241001529936 Murinae Species 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 13
- 239000000126 substance Substances 0.000 description 12
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 10
- 210000004698 lymphocyte Anatomy 0.000 description 10
- 102000015696 Interleukins Human genes 0.000 description 9
- 108010063738 Interleukins Proteins 0.000 description 9
- 108091036066 Three prime untranslated region Proteins 0.000 description 8
- 206010009887 colitis Diseases 0.000 description 8
- 201000004624 Dermatitis Diseases 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 239000005557 antagonist Substances 0.000 description 7
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 7
- 210000003719 b-lymphocyte Anatomy 0.000 description 7
- 230000001684 chronic effect Effects 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 230000008685 targeting Effects 0.000 description 7
- 241000124008 Mammalia Species 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 108700028369 Alleles Proteins 0.000 description 5
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 5
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 210000003519 mature b lymphocyte Anatomy 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 101100508567 Mus musculus Il7 gene Proteins 0.000 description 4
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 108040006861 interleukin-7 receptor activity proteins Proteins 0.000 description 4
- 210000005087 mononuclear cell Anatomy 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 3
- 208000003950 B-cell lymphoma Diseases 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000043131 MHC class II family Human genes 0.000 description 3
- 108091054438 MHC class II family Proteins 0.000 description 3
- 206010042971 T-cell lymphoma Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000011712 cell development Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 238000012239 gene modification Methods 0.000 description 3
- 230000005017 genetic modification Effects 0.000 description 3
- 235000013617 genetically modified food Nutrition 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000000287 oocyte Anatomy 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 230000002992 thymic effect Effects 0.000 description 3
- 108020005065 3' Flanking Region Proteins 0.000 description 2
- 108020005345 3' Untranslated Regions Proteins 0.000 description 2
- 108020005029 5' Flanking Region Proteins 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 2
- 241000398750 Muroidea Species 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011813 knockout mouse model Methods 0.000 description 2
- 208000019420 lymphoid neoplasm Diseases 0.000 description 2
- 230000001589 lymphoproliferative effect Effects 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 238000011714 129 mouse Methods 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 241001330002 Bambuseae Species 0.000 description 1
- 241001529504 Brachytarsomys albicauda Species 0.000 description 1
- 108700031361 Brachyury Proteins 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 101100000858 Caenorhabditis elegans act-3 gene Proteins 0.000 description 1
- 241000398949 Calomyscidae Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 241000398985 Cricetidae Species 0.000 description 1
- 241001095404 Dipodoidea Species 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000614436 Homo sapiens Keratin, type I cytoskeletal 14 Proteins 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000010782 Interleukin-7 Receptors Human genes 0.000 description 1
- 108010038498 Interleukin-7 Receptors Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010025327 Lymphopenia Diseases 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- 241000699729 Muridae Species 0.000 description 1
- 241000398990 Nesomyidae Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000393460 Peromyscus nasutus Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 241001338313 Platacanthomyidae Species 0.000 description 1
- 102000000434 Pre-B Cell Receptors Human genes 0.000 description 1
- 108010016231 Pre-B Cell Receptors Proteins 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 241000398956 Spalacidae Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 201000011176 T-cell adult acute lymphocytic leukemia Diseases 0.000 description 1
- 101150052863 THY1 gene Proteins 0.000 description 1
- 208000002903 Thalassemia Diseases 0.000 description 1
- 241001105470 Valenzuela Species 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000007402 cytotoxic response Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 210000003595 dermal dendritic cell Anatomy 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 235000003869 genetically modified organism Nutrition 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000009675 homeostatic proliferation Effects 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000011577 humanized mouse model Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 231100001023 lymphopenia Toxicity 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000000472 morula Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 208000017426 precursor B-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5418—IL-7
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0387—Animal model for diseases of the immune system
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0393—Animal model comprising a reporter system for screening tests
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Environmental Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Catching Or Destruction (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261660976P | 2012-06-18 | 2012-06-18 | |
| US61/660,976 | 2012-06-18 | ||
| US201261740074P | 2012-12-20 | 2012-12-20 | |
| US61/740,074 | 2012-12-20 | ||
| US13/795,765 | 2013-03-12 | ||
| US13/795,765 US8962913B2 (en) | 2012-06-18 | 2013-03-12 | Humanized IL-7 rodents |
| PCT/US2013/045788 WO2013192030A1 (en) | 2012-06-18 | 2013-06-14 | Humanized il-7 rodents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20150027752A true KR20150027752A (ko) | 2015-03-12 |
Family
ID=49757275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020147035047A Ceased KR20150027752A (ko) | 2012-06-18 | 2013-06-14 | 인간화된 il-7 설치류 |
Country Status (27)
| Country | Link |
|---|---|
| US (7) | US8962913B2 (enExample) |
| EP (2) | EP2859793B1 (enExample) |
| JP (1) | JP6174134B2 (enExample) |
| KR (1) | KR20150027752A (enExample) |
| CN (2) | CN105779467A (enExample) |
| AU (1) | AU2013277457B2 (enExample) |
| BR (1) | BR112014029892A2 (enExample) |
| CA (1) | CA2873134A1 (enExample) |
| CY (1) | CY1119071T1 (enExample) |
| DK (1) | DK2859793T3 (enExample) |
| ES (1) | ES2626965T3 (enExample) |
| HK (1) | HK1203761A1 (enExample) |
| HR (1) | HRP20170974T1 (enExample) |
| HU (1) | HUE034592T2 (enExample) |
| IL (3) | IL235773B (enExample) |
| IN (1) | IN2014DN10189A (enExample) |
| LT (1) | LT2859793T (enExample) |
| MX (1) | MX363540B (enExample) |
| NZ (1) | NZ702943A (enExample) |
| PL (1) | PL2859793T3 (enExample) |
| PT (1) | PT2859793T (enExample) |
| RS (1) | RS56039B1 (enExample) |
| RU (1) | RU2654565C2 (enExample) |
| SG (3) | SG10201609576YA (enExample) |
| SI (1) | SI2859793T1 (enExample) |
| SM (1) | SMT201700313T1 (enExample) |
| WO (1) | WO2013192030A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210108828A (ko) | 2020-02-26 | 2021-09-03 | 차의과학대학교 산학협력단 | 동물 면역계의 인간화 활성을 촉진하는 방법 |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3028565B1 (en) | 2009-07-08 | 2017-09-27 | Kymab Limited | Animal models and therapeutic molecules |
| EP2757875B2 (en) | 2011-09-19 | 2023-03-22 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
| US9001798B2 (en) * | 2012-03-05 | 2015-04-07 | Samsung Electronics Co., Ltd. | HARQ-ACK signal transmission in response to detection of control channel type in case of multiple control channel types |
| US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
| US8962913B2 (en) * | 2012-06-18 | 2015-02-24 | Regeneron Pharmaceuticals, Inc. | Humanized IL-7 rodents |
| US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
| US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
| US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
| SMT202500280T1 (it) | 2013-09-23 | 2025-09-12 | Regeneron Pharma | Animali non umani aventi un gene umanizzato della proteina regolatrice del segnale |
| WO2015049517A2 (en) | 2013-10-01 | 2015-04-09 | Kymab Limited | Animal models and therapeutic molecules |
| TR201904342T4 (tr) | 2013-10-15 | 2019-05-21 | Regeneron Pharma | Hümani̇ze il-15 hayvanlar |
| EP3430898A1 (en) | 2013-11-19 | 2019-01-23 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized a proliferation-inducing ligand gene |
| US9795121B2 (en) * | 2014-05-05 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Humanized C3 animals |
| NO2785538T3 (enExample) | 2014-05-07 | 2018-08-04 | ||
| ES2969389T3 (es) | 2014-12-05 | 2024-05-17 | Regeneron Pharma | Animales no humanos que tienen un gen del grupo de diferenciación 47 humanizado |
| SG10202103445QA (en) * | 2015-04-13 | 2021-05-28 | Regeneron Pharma | Humanized sirpa-il15 knockin mice and methods of use thereof |
| US10582702B2 (en) | 2016-02-04 | 2020-03-10 | Regeneron Pharmaceuticals, Inc. | Non-human animals having an engineered ANGPTL8 gene |
| CA3014645C (en) | 2016-02-29 | 2022-10-25 | Regeneron Pharmaceuticals, Inc. | Rodents having a humanized tmprss gene |
| EP3585162B1 (en) | 2017-09-29 | 2023-08-30 | Regeneron Pharmaceuticals, Inc. | Rodents comprising a humanized ttr locus and methods of use |
| HUE067361T2 (hu) | 2018-07-16 | 2024-10-28 | Regeneron Pharma | Ditra betegség rágcsáló modelljei és alkalmazásaik |
| CN111218425B (zh) * | 2019-01-17 | 2022-02-08 | 百奥赛图(北京)医药科技股份有限公司 | 人源化转基因动物 |
| AU2020253532B2 (en) | 2019-04-04 | 2024-06-20 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized coagulation factor 12 locus |
| WO2020247452A1 (en) | 2019-06-04 | 2020-12-10 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use |
| SG11202111256XA (en) | 2019-06-07 | 2021-11-29 | Regeneron Pharma | Non-human animals comprising a humanized albumin locus |
| US20220312749A1 (en) * | 2019-08-09 | 2022-10-06 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animal with human or chimeric il2ra |
| JP2023511626A (ja) * | 2020-01-28 | 2023-03-20 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒト化ｐｎｐｌａ３遺伝子座を含む非ヒト動物および使用方法 |
| CN111926039B (zh) * | 2020-09-23 | 2021-03-16 | 百奥赛图(北京)医药科技股份有限公司 | Il-13基因人源化的非人动物的构建方法和应用 |
| CN116802200A (zh) * | 2020-12-21 | 2023-09-22 | 瑞泽恩制药公司 | 具有人源化tslp基因、人源化tslp受体基因和/或人源化il7ra基因的非人动物 |
| WO2022247936A1 (en) * | 2021-05-28 | 2022-12-01 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animal with human or chimeric cd36 |
| KR20250067149A (ko) * | 2022-09-08 | 2025-05-14 | 더 잭슨 래보라토리 | 인간화 면역결핍 마우스 모델 |
| WO2025212991A1 (en) | 2024-04-05 | 2025-10-09 | Regeneron Pharmaceuticals, Inc. | Rodent models of disease |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA887773B (en) * | 1987-10-26 | 1989-07-26 | Immunex Corp | Interleukin-7 |
| CA2382383A1 (en) | 1999-08-31 | 2001-03-08 | Genencor International, Inc. | Transgenic mammal capable of facilitating production of donor-specific functional immunity |
| US7759541B2 (en) | 2004-12-13 | 2010-07-20 | Iti Life Sciences | Transgenic animals for assessing drug metabolism and toxicity |
| GB2434578A (en) | 2006-01-26 | 2007-08-01 | Univ Basel | Transgenic animals |
| CN101302517B (zh) * | 2008-02-03 | 2010-11-03 | 中国科学院广州生物医药与健康研究院 | 人白细胞介素7在真核宿主中表达的方法 |
| EP3417701B1 (en) * | 2009-10-06 | 2021-12-15 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice and engraftment |
| RU2577978C2 (ru) | 2011-02-15 | 2016-03-20 | Ридженерон Фармасьютикалз, Инк. | Гуманизированные m-csf мыши |
| RU2751240C2 (ru) | 2011-10-28 | 2021-07-12 | Регенерон Фармасьютикалс, Инк. | Гуманизированные il-6 и рецептор il-6 |
| US8962913B2 (en) | 2012-06-18 | 2015-02-24 | Regeneron Pharmaceuticals, Inc. | Humanized IL-7 rodents |
-
2013
- 2013-03-12 US US13/795,765 patent/US8962913B2/en not_active Expired - Fee Related
- 2013-06-14 CN CN201610168011.XA patent/CN105779467A/zh active Pending
- 2013-06-14 PL PL14195502T patent/PL2859793T3/pl unknown
- 2013-06-14 SG SG10201609576YA patent/SG10201609576YA/en unknown
- 2013-06-14 BR BR112014029892A patent/BR112014029892A2/pt not_active Application Discontinuation
- 2013-06-14 DK DK14195502.1T patent/DK2859793T3/en active
- 2013-06-14 SG SG11201407370QA patent/SG11201407370QA/en unknown
- 2013-06-14 LT LTEP14195502.1T patent/LT2859793T/lt unknown
- 2013-06-14 AU AU2013277457A patent/AU2013277457B2/en not_active Ceased
- 2013-06-14 SM SM20170313T patent/SMT201700313T1/it unknown
- 2013-06-14 SG SG10201609569PA patent/SG10201609569PA/en unknown
- 2013-06-14 SI SI201330664A patent/SI2859793T1/sl unknown
- 2013-06-14 MX MX2014015679A patent/MX363540B/es unknown
- 2013-06-14 HU HUE14195502A patent/HUE034592T2/en unknown
- 2013-06-14 RU RU2014148107A patent/RU2654565C2/ru not_active IP Right Cessation
- 2013-06-14 HK HK15104315.3A patent/HK1203761A1/xx unknown
- 2013-06-14 EP EP14195502.1A patent/EP2859793B1/en active Active
- 2013-06-14 EP EP13739875.6A patent/EP2861063A1/en not_active Withdrawn
- 2013-06-14 NZ NZ702943A patent/NZ702943A/en not_active IP Right Cessation
- 2013-06-14 JP JP2015517447A patent/JP6174134B2/ja not_active Expired - Fee Related
- 2013-06-14 WO PCT/US2013/045788 patent/WO2013192030A1/en not_active Ceased
- 2013-06-14 PT PT141955021T patent/PT2859793T/pt unknown
- 2013-06-14 ES ES14195502.1T patent/ES2626965T3/es active Active
- 2013-06-14 KR KR1020147035047A patent/KR20150027752A/ko not_active Ceased
- 2013-06-14 RS RS20170543A patent/RS56039B1/sr unknown
- 2013-06-14 CN CN201380031333.4A patent/CN104378976B/zh not_active Expired - Fee Related
- 2013-06-14 CA CA2873134A patent/CA2873134A1/en not_active Abandoned
-
2014
- 2014-11-18 IL IL235773A patent/IL235773B/en active IP Right Grant
- 2014-11-24 US US14/551,538 patent/US9232776B2/en not_active Expired - Fee Related
- 2014-11-28 IN IN10189DEN2014 patent/IN2014DN10189A/en unknown
-
2015
- 2015-11-10 US US14/937,270 patent/US20160052986A1/en not_active Abandoned
-
2016
- 2016-11-21 US US15/357,021 patent/US9737059B2/en not_active Expired - Fee Related
-
2017
- 2017-05-31 CY CY20171100577T patent/CY1119071T1/el unknown
- 2017-06-27 HR HRP20170974TT patent/HRP20170974T1/hr unknown
- 2017-07-14 US US15/649,797 patent/US9974291B2/en not_active Expired - Fee Related
-
2018
- 2018-04-24 US US15/960,642 patent/US10314298B2/en not_active Expired - Fee Related
- 2018-06-25 IL IL260250A patent/IL260250B/en not_active IP Right Cessation
-
2019
- 2019-05-01 US US16/400,074 patent/US20190343093A1/en not_active Abandoned
- 2019-08-13 IL IL26867419A patent/IL268674A/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210108828A (ko) | 2020-02-26 | 2021-09-03 | 차의과학대학교 산학협력단 | 동물 면역계의 인간화 활성을 촉진하는 방법 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2013277457B2 (en) | Humanized IL-7 rodents | |
| KR102291355B1 (ko) | Pd-l1 억제제 공동치료를 필요로 하는 환자의 식별방법 | |
| AU2015286663B2 (en) | Antisense oligonucleotides for the treatment of usher syndrome type 2 | |
| KR101778036B1 (ko) | 전립선암 마커로서의 포스포디에스테라제 4ｄ7 | |
| KR20210138587A (ko) | 개선된 면역요법을 위한 조합 유전자 표적 | |
| KR20230034198A (ko) | 종양 침윤 림프구의 활성화 및 확장 방법 | |
| AU2016325030A1 (en) | Novel biomarkers and methods of treating cancer | |
| AU2018364916B2 (en) | Therapeutic pharmaceutical composition for cancer including miRNA | |
| KR102424119B1 (ko) | 저하된 상위 및 하위 운동 뉴런 기능 및 감각 지각을 나타내는 비-인간 동물 | |
| KR20220025806A (ko) | 핵산의 무작위 구성 표적화 통합 | |
| KR20080096495A (ko) | 소과 동물에서 배최장근 최대력, 근내 지방, 식용우소매유통 생산량 및 순 사료 섭취량으로부터 선택된 형질을평가하는 방법 | |
| CN101151371B (zh) | 治疗中的逆转录转座子抑制 | |
| KR20230074214A (ko) | 지방간 질환의 치료 방법 | |
| AU2019339404B2 (en) | Complement factor h gene knockout rat as a model of C3 glomerulopathy | |
| US20160250182A1 (en) | Rab7l1 interacts with lrrk2 to modify intraneuronal protein sorting and parkinson's disease risk | |
| CN113473850A (zh) | 具有遗传修饰的钠通道的啮齿动物及其使用方法 | |
| CA2474759A1 (en) | Gene for peripheral arterial occlusive disease | |
| CN116802200A (zh) | 具有人源化tslp基因、人源化tslp受体基因和/或人源化il7ra基因的非人动物 | |
| US20160184454A1 (en) | Rab7l1 interacts with lrrk2 to modify intraneuronal protein sorting and parkinson's disease risk | |
| CN108135151A (zh) | 前列腺癌的啮齿动物模型 | |
| CN113817770B (zh) | Cd73基因人源化的非人动物的构建方法及应用 | |
| RU2839460C1 (ru) | Лечение ожирения у субъектов молекулами вариантов нуклеиновых кислот, кодирующими рецептор кальцитонина (calcr) | |
| US20040238597A1 (en) | Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof | |
| EA048246B1 (ru) | Способ лечения жировой болезни печени | |
| US20030224393A1 (en) | Gene for peripheral arterial occlusive disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20141212 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20180516 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20191022 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20191230 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20191022 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |